EANS-Adhoc: Epigenomics AG: General Assembly Approves all Proposals including Reduction of Share Capital with vast majority

   

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information/molecular diagnostic

28.06.2011

Berlin, Germany, June 28, 2011 - Epigenomics AG`s (ISIN: DE000A0BVT96) General
Assembly today approved all decision proposals by the management with vast
majority.

The proposal to reduce the share capital and to consolidate of the shares at a
ratio of 5:1 was approved with more than 99.8 % of the present and represented
voting rights. Following this approval, the capital shall be reduced from now
EUR 44,092,085.00 to EUR 8,818,417.00. After the consolidation of the shares,
the share capital shall be distributed into 8,818,417 shares. The reduction of
share capital becomes effective only after its registration in the commercial
register. The consolidation of the shares shall follow thereafter in the
subsequent trading days.

An overview of all voting results of the General Assembly is available at
Epigenomics AG´s internet page.

-End of Ad hoc -

Further Information

For the voting results and further information on Epigenomics AG´s Annual
General Shareholder´s Meeting please visit
http://www.epigenomics.com/news-investors/investor-relations/hauptversammlung.html


Contact Epigenomics AG                 
Dr. Achim Plum                         
Sen. VP Corporate Development          
Epigenomics AG                         
Phone: +49 (0) 30 24345 0              
ir@epigenomics.com                     
www.epigenomics.com                 


Epigenomics´ legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results, financial
condition, performance or achievements of Epigenomics AG to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
future events or otherwise.


Further inquiry note:
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel: +49 30 24345 368
achim.plum@epigenomics.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      Epigenomics AG
             Kleine Präsidentenstraße 1
             D-10178 Berlin
phone:       +49 30 24345-0
FAX:         +49 30 24345-555
mail:     ir@epigenomics.com
WWW:      www.epigenomics.com
sector:      Biotechnology
ISIN:        DE000A0BVT96, DE000A0XFWF2
indexes:     Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, München 
language:   English